Glanbia’s (GLAPF) Buy Rating Reaffirmed at Kepler Capital Markets

Kepler Capital Markets reaffirmed their buy rating on shares of Glanbia (OTCMKTS:GLAPF) in a report released on Sunday, reports.

GLAPF has been the topic of several other research reports. Credit Suisse Group assumed coverage on shares of Glanbia in a research note on Tuesday, September 1st. They set an outperform rating on the stock. Morgan Stanley reiterated an overweight rating on shares of Glanbia in a research note on Friday, August 14th.

GLAPF opened at $10.50 on Friday. Glanbia has a fifty-two week low of $9.30 and a fifty-two week high of $12.76. The company’s 50-day moving average price is $10.48 and its 200 day moving average price is $10.93.

About Glanbia

Glanbia plc operates as a nutrition company. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, e-Commerce, and gyms, as well the food, drug, mass, and club channels.

Featured Article: What is the return on assets (ROA) ratio?

Receive News & Ratings for Glanbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glanbia and related companies with's FREE daily email newsletter.